(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post' - 2Hezbollah sees potential win as Israel backs down from disarmament goal
- 3Triumph's 400 Range Has Just Changed In India, And Here's Why
- 4Wegmans recalls mixed nuts over salmonella contamination fears
- 5New ‘Cloud-9’ object could reveal the secrets of dark matter
- The Best Games Crossroads in History
- The biggest black hole breakthroughs of 2025
- Smuggler who called migrants 'chickens' jailed
- The Best 20 Photography Instagram Records to Follow
- Australia to offer businesses $693 million in cheap loans to ease fuel cost pressure
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
